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Gender differences in CNV burden 
do not confound schizophrenia CNV 
associations
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Compared with the general population, an excess of rare copy number variants (CNVs) has been 
identified in people with schizophrenia. Females with neurodevelopmental disorders and in the 
general population have been reported to carry more large, rare CNVs than males. Given that many 
schizophrenia datasets do not have equal gender ratios in cases and controls, sex differences in CNV 
burden might have impacted on estimates of case-related CNV burden and also on associations to 
individual loci. In a sample of 13,276 cases and 17,863 controls, we observed a small but significant 
excess of large (≥500 Kb), rare (<1%) CNVs in females compared with males in both cases and controls 
(OR = 1.17, P = 0.0012 for controls; OR = 1.11, P = 0.045 for cases). The burden of 11 schizophrenia-
associated CNVs was significantly higher in female cases compared with male cases (OR = 1.38, 
P = 0.0055), but after accounting for the rates of CNVs in controls, we found no significant gender 
difference in the risk conferred by these loci. Controlling for gender had a negligible effect on the 
significance of association between specific CNVs and schizophrenia. The female excess of large CNVs in 
both cases and controls suggests a female protective mechanism exists for deleterious CNVs that may 
extend beyond neurodevelopmental phenotypes.
Schizophrenia has a strong genetic component involving rare and common alleles distributed across many 
genes1,2. Common alleles confer weak effects (OR < 1.1 in general) but collectively account for a substantial pro-
portion of genetic liability to the disorder3. On the other hand, some rare genetic variants, such as copy number 
variants (CNVs), confer larger risks for schizophrenia4,5. A combined analysis of published datasets has shown 
strong evidence for association between 11 individual CNVs and risk of schizophrenia and weaker evidence for 
4 additional risk CNVs6. Duplications of 22q11.2 have also been associated with reduced risk of schizophrenia7.
A gender-bias in prevalence has been repeatedly observed in neurodevelopmental disorders. In autism spec-
trum disorder (ASD), the mean male-to-female ratio is about 4:18, whereas in schizophrenia the male-to-female 
ratio is 1.4:1, though this varies by age reflecting sex related differences in age at onset9. Sex differences in schiz-
ophrenia have also been reported for structural and functional brain abnormalities whose origins are thought to 
occur during brain development10–14.
A recent study found an excess of deleterious autosomal CNVs in females compared with males in a neurode-
velopmental disorders cohort and in an ASD cohort15. Females with ASD have also been found to possess a higher 
burden of de novo CNVs and genes disrupted by de novo CNVs than males with ASD16–18. The lower prevalence 
of ASD and higher mutational burden in females with the disorder is consistent with a different liability threshold 
for females compared to males whereby females require a greater risk factor load to manifest neurodevelopmental 
disorders15,19,20. A higher female autosomal burden of large, rare CNVs, attributed to lower rates of foetal loss, has 
also been reported in the general population21.
Given the excess burdens of CNVs in females in both neurodevelopmental and control samples, we tested 
whether similar differences in burden exist in schizophrenia using a large case control dataset (N = 31,139 indi-
viduals). We evaluated the CNV burden in females and males at a genome-wide level and for 11 strongly asso-
ciated schizophrenia risk loci. We also tested whether association between specific CNVs and schizophrenia are 
robust to adjusting for gender. Consistent with earlier findings, we found an increased CNV burden for large 
(≥ 500 Kb), rare (< 1%) CNVs in female controls and now report an excess in female cases with the disorder. 
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Although female cases also had an excess burden compared with males for 11 CNVs that have been implicated 
in schizophrenia, the association between those CNVs and schizophrenia was not diminished after controlling 
for gender.
Results
Females carry an excess of CNVs both genome-wide and at specific loci. Females had a genome-
wide excess of large (≥ 500 kb) and rare (< 1%) CNVs in cases (OR = 1.11, 95% CI = 1.00–1.23, P = 0.045) and 
controls (OR = 1.17, 95% CI = 1.06–1.29, P = 0.0012) (Fig. 1, Supplementary Table S1) although only in female 
controls would this survive correction (P = 0.0048) for 4 independent tests (CNVs < 500kb and CNV ≥ 500 kb 
separately for cases and controls). While the excess CNV burden in female cases does not survive correction 
for multiple testing, importantly the size of the effect is not significantly different from that in female controls 
(Z-test P = 0.24). The effect size for schizophrenia conferred by all large, rare CNVs in females (OR = 1.24, 95% 
CI = 1.12–1.38, P = 8.22 × 10−5) and in males (OR = 1.32, 95% CI = 1.20–1.45, P = 4.13 × 10−9) did not statisti-
cally differ (Z-test P = 0.19).
When deletions and duplications were analysed separately (Supplementary Table S1), we found that the con-
tribution from large deletions to the excess of CNVs in control females was significantly greater than that from 
large duplications (Z-test P = 0.013). In cases, no significant difference was observed between the contribution 
of large deletions and duplications to the CNV excess in females (Z-test P = 0.44, Supplementary Table S1). No 
difference in the burden of smaller CNVs (< 500 kb) was observed between males and females for cases or con-
trols (Fig. 1, Supplementary Table S1). A breakdown of CNV burden in the datasets that constitute our case and 
control samples can be found in Supplementary Table S2. Despite the excess burden of large deletions in female 
controls, we found no significant difference between males and females for the number of genes overlapping 
CNVs for any class of CNV tested (Supplementary Table S3).
The burden of 11 schizophrenia risk CNVs was significantly higher in female cases than male cases (OR = 1.38, 
95% CI = 1.10–1.73, P = 0.0055) but not in female controls compared with male controls (OR = 1.12, 95% 
CI = 0.80–1.55, P = 0.52) (Fig. 1, Supplementary Table S1). However, the difference in effect size between these 
two tests did not significantly differ (Z-test P = 0.15). When we compared the risk for schizophrenia conferred 
by the set of 11 CNV loci in females (OR = 3.56, 95% CI = 2.66–4.75, P = 2.06 × 10−18) and males (OR = 2.85, 
95% CI = 2.15–3.76, P = 3.66 × 10−15), we found no significant difference in effect size (Z test P = 0.14). Hence, 
the non-significant test by sex in the controls might reflect lower power given that (by definition) there are fewer 
observations of these pathogenic CNVs in controls.
Association of specific CNVs with schizophrenia is not confounded by gender. Table 1 shows 
association statistics between individual CNVs and schizophrenia. These CNVs include 11 known schizophre-
nia risk loci, 4 additional risk CNVs that have yet to be implicated in schizophrenia with strong evidence, and 
1 protective CNV (see methods for detail). Controlling for gender had a negligible effect on the significance of 
association between specific CNVs and schizophrenia. Table S4 presents a breakdown of these associations for the 
individual datasets (CLOZUK, ISC and MGS).
Figure 1. Gender CNV burden in the combined dataset. CNV burden is compared between males and 
females for both case and control samples. The combined CLOZUK, MGS and ISC dataset consists of 9,172 
male and 4,104 female case samples, and 8,807 male and 9,056 female control samples.
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Discussion
We have carried out an analysis of gender stratified CNV burden in schizophrenia at both a genome-wide level 
and for previously associated loci. We restricted our analysis to the autosome as sex chromosomal CNVs were not 
available for all samples. We found a genome-wide excess of large, rare CNVs in females compared with males, 
irrespective of disease status. Similar observations have been reported in ASD and general population cohorts15,21. 
We also report an excess burden of CNVs at 11 schizophrenia risk loci in female cases compared with male cases, 
an observation that is reminiscent of an excess of deleterious variants in females with childhood neurodevelop-
mental disorders15. However, when males and females were analysed separately, we found no difference in effect 
size for risk of schizophrenia conferred by the total burden of the 11 associated loci. Moreover, association of indi-
vidual CNV loci was not affected when statistical tests were used that accounted for gender. These results confirm 
that associations between schizophrenia and 11 specific risk CNVs and the protective 22q11.2 duplication are 
robust to differences in gender proportion in case and control samples. The weaker evidence for 4 additional risk 
CNVs cannot be attributed to gender related heterogeneity. Interestingly, despite the excess number of CNVs in 
females, we found no significant difference by sex in the number of genes disrupted by CNVs, suggesting that on 
average, CNVs are less gene-dense in females than they are in males.
At a genome-wide level, an excess female CNV burden was only observed for large CNVs (≥ 500 kb). However, 
we cannot confidently exclude a similar effect from smaller CNVs given the limited resolution to which microar-
rays can accurately call CNVs. When deletions and duplications ≥ 500 Kb were analysed separately, we found that 
deletions primarily accounted for the excess genome-wide CNV burden seen in female controls.
Recent findings of an excess mutational burden in females provide support for the view that females are rela-
tively protected from neurodevelopmental disorders15,17–19,22,23. Schizophrenia is now generally considered to be 
at least in part a neurodevelopmental disorder; it is known to share genetic risk alleles with autism and other neu-
rodevelopmental disorders24,25 and there is also an excess risk of the disorder in males, albeit much more modest 
than it is for other neurodevelopmental disorders such as ID, ASD and ADHD. The excess burden of CNVs in 
females might be considered evidence for female robustness to schizophrenia but caution is required given the 
pattern of findings in controls. As we and others21 have shown, female controls also have higher rates of large, rare 
CNVs, which in general are the class of CNV that contribute to neurodevelopmental disorders. This elevation in 
rate of CNVs in both cases and controls could potentially point to a mechanism that goes beyond protection from 
disorders such as ASD and schizophrenia: for example, protection from female foetal loss or premature death 
(pre- or post-natal). However, to address this question requires truly representative population cohorts as the 
gender CNV bias in controls might be an artefact resulting from female protection from conditions (including 
neurodevelopmental disorders) that would normally result in exclusion from control cohorts.
It is clear that CNV burden differs between males and females in both patients diagnosed with neurodevelop-
mental disorders, such as schizophrenia, and also in the general population. However, our data indicate that var-
iation in gender CNV burden does not impact on known schizophrenia-CNV associations. We provide further 
evidence that in both case and control samples, the rate of deleterious CNVs is greater in females than in males, 
although investigating the reason for this will require large population cohorts.
Locus
NCNV in cases 
(Frequency, % in 
males/% in females)
NCNV in controls 
(Frequency, % in 
males/% in females)
SCZ association SCZ association controlled for gender
Odds Ratio (95% CI)
P-value (two-sided 
Fisher’s Exact test) Odds Ratio (95% CI)
P-value (two-sided 
Cochran-Mantel-
Haenszel Exact test)
15q11.2 del§ 84 (0.57/0.78) 73 (0.43/0.39) 1.55 (1.12–2.16) 0.0074 1.59 (1.14–2.22) 0.0050
15q13.3 del§ 17 (0.14/0.10) 4 (0.01/0.03) 5.73 (1.87–23.39) 0.00053 5.66 (1.81–23.47) 0.00062
16p11.2 distal del* 5 (0.02/0.07) 4 (0.01/0.03) 1.68 (0.36–8.48) 0.51 2.12 (0.44–10.95) 0.30
16p11.2 dup§ 42 (0.31/0.34) 5 (0.02/0.03) 11.33 (4.49–36.68) 3.29 × 10−11 11.66 (4.57–38.08) 7.11 × 10−11
16p13.11 dup§ 42 (0.25/0.46) 40 (0.19/0.25) 1.41 (0.89–2.24) 0.12 1.55 (0.97–2.48) 0.065
17p12 del* 9 (0.03/0.15) 7 (0.01/0.07) 1.73 (0.57–5.47) 0.32 2.33 (0.76–7.50) 0.11
17q12 del* 2 (0.00/0.05) 0 (0.00/0.00) NA (0.25–∞ ) 0.18 NA (0.41–∞ ) 0.097
1q21.1 del§ 24 (0.16/0.22) 6 (0.03/0.03) 5.39 (2.15–16.13) 4.80 × 10−5 5.64 (2.21–17.10) 3.77 × 10−5
1q21.1 dup§ 16 (0.10/0.17) 8 (0.02/0.07) 2.69 (1.09–7.27) 0.022 3.11 (1.23–8.53) 0.0097
3q29 del§ 10 (0.05/0.12) 0 (0.00/0.00) NA (3.02–∞ ) 0.00020 NA (3.46–∞ ) 0.00010
22q11.2 del§ 48 (0.32/0.46) 0 (0.00/0.00) NA (16.90–∞ ) 1.61 × 10−18 NA (18.14–∞ ) 7.70 × 10−19
22q11.2 dup^ 2 (0.01/0.02) 17 (0.07/0.12) 0.15 (0.02–0.67) 0.0043 0.18 (0.02–0.77) 0.014
NRXN1 del§ 24 (0.16/0.22) 5 (0.05/0.01) 6.47 (2.42–21.71) 1.34 × 10−5 6.48 (2.38–22.02) 2.57 × 10−5
PWS/AS dup§ 11 (0.09/0.08) 0 (0.00/0.00) NA (3.38–∞ ) 8.44 × 10−5 NA (3.36–∞ ) 8.49 × 10−5
VIPR2 dup* 12 (0.11/0.05) 14 (0.07/0.09) 1.15 (0.49–2.69) 0.84 1.12 (0.46–2.67) 0.84
WBS dup§ 6 (0.05/0.04) 2 (0.00/0.02) 4.04 (0.72–40.93) 0.080 5.10 (0.94–51.62) 0.037
Table 1.  Effect of gender stratification on schizophrenia CNV associations. Association between 
schizophrenia and CNVs at 15 specific risk loci and the protective 22q11.2 duplication locus. Association 
statistics are calculated with a Fisher’s Exact test (two-sided) and a Cochran-Mantel-Haenszel Exact test (two-sided) 
stratified by gender. SCZ = schizophrenia, PWS/AS = Prader-Willi/Angelman syndrome. WBS = Williams-Beuren 
syndrome. §Risk locus (strong evidence). *Risk locus (weaker evidence). ^Protective locus.
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Methods
Study samples and QC. Case and control CNVs were derived from three published samples: CLOZUK6, 
the ISC4 and the MGS26. A full description of these samples, the arrays they were genotyped on, and CNV calling 
procedures can be found in the original publications4,6,26. Quality control was performed to remove low quality 
samples (see original publications), and details of those samples that passed quality control in each study can be 
found elsewhere6. We excluded samples of unknown gender (sex chromosome molecular genetic data were not 
available for all samples) and putative CNVs < 15 kb in size and/or covered by < 15 probes. After filtering, a total 
of 31,139 individuals were included in the current study (17,959 from CLOZUK and its corresponding controls, 
6,600 from MGS and 6,580 from the ISC, Table 2). All CNVs have a population frequency < 1%.
Selection of specific schizophrenia-associated CNVs. We tested the burden of 11 schizophrenia risk 
CNV loci that showed significant association with schizophrenia in our previous publication6; deletions at 1q21.1, 
NRXN1 (exonic CNVs only), 3q29, 15q11.2, 15q13.3 and 22q11.2; duplications at 1q21.1, 16p11.2 and 16p13.11, 
the Prader-Willi/Angelman syndrome (PWS/AS) region and Williams-Beuren syndrome (WBS) region. In our 
analysis of individual CNV loci, we tested these 11 schizophrenia risk CNVs, along with previously implicated 
risk CNVs for which the overall evidence is less strong6, postulating some of the variable evidence here might be 
due to gender related heterogeneity. These included duplications of VIPR2, deletions of 17p12, 17q12 and distal 
16p11.2. We also tested the impact of gender on protective effects for 22q11.2 duplication7.
Statistical analysis. We tested for CNV burden (≥ 500 kb; < 500 kb) and burden of 11 schizophrenia risk 
loci in females versus males by comparing the change in deviance between the following logistic regression mod-
els (R glm function, family = binomial(“logit”)) using a two-sided test (ANOVA). Odds ratios (ORs) were derived 
from the correlation coefficients for number of CNVs.
1. logit (pr (gender)) ~ number of CNVs + study source + microarray platform 
2. logit (pr (gender)) ~ study source + microarray platform
To test whether females had more genes disrupted by CNVs than males, a similar analysis was performed 
where ‘number of CNVs’ in the above model was replaced with ‘number of genes overlapping CNVs’.
To test whether the risk of schizophrenia conferred by large CNVs (≥ 500 kb) or the set of 11 specific schiz-
ophrenia CNVs is significantly different for females and males, we compared the effect size in females with the 
effect size in males using the coefficients and standard errors (Z-test, see below) derived from the following logis-
tic regression model (R glm function, family = binomial(“logit”)):
logit (pr(case)) ~ number of schizophrenia CNVs + study source + microarray platform
We note that almost identical P values were obtained when the above model was replaced with Firth’s proce-
dure27 (data not shown).
Differences in effect size between tests were evaluated with a Z-test, which was constructed using the 
equation (1)
β β
σ σ
=
−
+
Z 1 2
(( 1) ( 2) ) (1)2 2
where β is the coefficient for the variable of interest taken from the regression model and σ is that variable’s stand-
ard error. P values were generated by comparing the absolute of the Z statistic against the cumulative distribution 
function of the standard normal distribution.
To assess whether a difference in gender proportion between cases and controls confounds association 
between schizophrenia and specific CNVs, we calculated individual locus association statistics using a Fisher’s 
Exact test (two-sided) and a Cochran-Mantel-Haenszel Exact test (two-sided) that was stratified by gender.
All statistical tests were conducted using R Statistical Software (https://www.r-project.org).
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